Beverly Hills Cancer Center

ROR: 00j1j3213

OpenAlex ID: I4210100502

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

2015 · Antoni Ribas, Igor Puzanov, et al. · The Lancet Oncology · 1,572

PDF

Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

2014 · Grant A McArthur, Paul B Chapman, et al. · The Lancet Oncology · 979

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

2023 · Alexander M. Lesokhin, Michael H. Tomasson, et al. · Nature Medicine · 652

PDF

An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)

2014 · Olivier Bruyère, Cyrus Cooper, et al. · Seminars in Arthritis and Rheumatism · 515

PDF

Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma

2013 · Steven J. O'Day, Alexander M.M. Eggermont, et al. · Journal of Clinical Oncology · 374

PDF

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

2013 · Jedd D. Wolchok, F. Stephen Hodi, et al. · Annals of the New York Academy of Sciences · 303

PDF

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma

2016 · Karen L. Reckamp, Vladislava O. Melnikova, et al. · Journal of Thoracic Oncology · 289

PDF

Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)

2013 · D. McDermott, J. Haanen, et al. · Annals of Oncology · 219

Standardising the descriptive epidemiology of osteoporosis: recommendations from the Epidemiology and Quality of Life Working Group of IOF

2013 · The Epidemiology and Quality of Life Working Group of IOF, J. A. Kanis, et al. · Osteoporosis International · 182

Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial

2020 · James Chih-Hsin Yang, D. Ross Camidge, et al. · Journal of Thoracic Oncology · 163

PDF

Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control

2013 · Caroline Robert, Dirk Schadendorf, et al. · Clinical Cancer Research · 151

Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

2015 · Richard D. Carvajal, Donald P. Lawrence, et al. · Clinical Cancer Research · 149

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies

2014 · C. Lebbé, J.S. Weber, et al. · Annals of Oncology · 143

PDF

Metastatic melanoma to the liver: A contemporary and comprehensive review of surgical, systemic, and regional therapeutic options

2013 · Sanjiv S. Agarwala, Alexander M. M. Eggermont, et al. · Cancer · 111

2016 · Dirk Schadendorf, Reinhard Dummer, et al. · European Journal of Cancer · 95

PDF

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma

2015 · Reinhard Dummer, Adil Daud, et al. · Journal of Translational Medicine · 94

PDF

Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials

2014 · Keith T Flaherty, Michael Hennig, et al. · The Lancet Oncology · 71

Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels

2014 · Anna M. Leung, Agnes Fermin Lee, et al. · Frontiers in Oncology · 58

PDF

Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers

2017 · Takeo Fujii, Afsaneh Barzi, et al. · Clinical Cancer Research · 55

PDF

Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)

2020 · David Spigel, Robert Jotte, et al. · Journal of Thoracic Oncology · 49

PDF

A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors

2018 · Gregory L. Beatty, Safi Shahda, et al. · The Oncologist · 46

PDF

Autologous Fat Transplantation: An Evaluation of Microcalcification and Fat Cell Survivability following (AFT) Cosmetic Breast Augmentation

1988 · Mel Bircoll · The American Journal of Cosmetic Surgery · 41

MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy

2023 · Kai He, David Berz, et al. · Journal of Thoracic Oncology · 36

PDF

Extranodal NK/T-cell Lymphoma, Nasal Type, Arising in Association With Saline Breast Implant

2012 · Tariq N. Aladily, Bharat N. Nathwani, et al. · The American Journal of Surgical Pathology · 35

Hypothesis: The Leukemias—Proliferative or Accumulative?

1967 · HOWARD R. BIERMAN · Blood · 33

PDF

Works count: 158

Citation count: 14,710